Myriad Genetics Statistics

Total Valuation

Myriad Genetics has a market cap or net worth of $555.36 million. The enterprise value is $642.46 million.

Market Cap	555.36M
Enterprise Value	642.46M

Important Dates

The next estimated earnings date is Tuesday, August 4, 2026, after market close.

Earnings Date	Aug 4, 2026
Ex-Dividend Date	n/a

Share Statistics

Myriad Genetics has 94.45 million shares outstanding. The number of shares has increased by 2.42% in one year.

Current Share Class	94.45M
Shares Outstanding	94.45M
Shares Change (YoY)	+2.42%
Shares Change (QoQ)	+0.43%
Owned by Insiders (%)	3.78%
Owned by Institutions (%)	82.62%
Float	78.78M

Valuation Ratios

PE Ratio	n/a
Forward PE	51.40
PS Ratio	0.67
Forward PS	0.63
PB Ratio	1.65
P/TBV Ratio	3.84
P/FCF Ratio	n/a
P/OCF Ratio	231.40
PEG Ratio	1.10

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.77
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.63.

Current Ratio	2.40
Quick Ratio	1.91
Debt / Equity	0.63
Debt / EBITDA	51.90
Debt / FCF	n/a
Interest Coverage	-4.64

Financial Efficiency

Return on equity (ROE) is -76.73% and return on invested capital (ROIC) is -15.04%.

Return on Equity (ROE)	-76.73%
Return on Assets (ROA)	-4.77%
Return on Invested Capital (ROIC)	-15.04%
Return on Capital Employed (ROCE)	-11.79%
Weighted Average Cost of Capital (WACC)	11.39%
Revenue Per Employee	$307,037
Profits Per Employee	-$148,111
Employee Count	2,700
Asset Turnover	0.99
Inventory Turnover	8.86

Taxes

In the past 12 months, Myriad Genetics has paid $100,000 in taxes.

Income Tax	100,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +14.84% in the last 52 weeks. The beta is 1.73, so Myriad Genetics's price volatility has been higher than the market average.

Beta (5Y)	1.73
52-Week Price Change	+14.84%
50-Day Moving Average	4.46
200-Day Moving Average	5.82
Relative Strength Index (RSI)	75.15
Average Volume (20 Days)	1,956,623

Short Selling Information

The latest short interest is 8.65 million, so 9.16% of the outstanding shares have been sold short.

Short Interest	8.65M
Short Previous Month	8.55M
Short % of Shares Out	9.16%
Short % of Float	10.98%
Short Ratio (days to cover)	4.93

Income Statement

In the last 12 months, Myriad Genetics had revenue of $829.00 million and -$399.90 million in losses. Loss per share was -$4.29.

Revenue	829.00M
Gross Profit	580.00M
Operating Income	-64.10M
Pretax Income	-399.80M
Net Income	-399.90M
EBITDA	-12.30M
EBIT	-64.10M
Loss Per Share	-$4.29

Full Income Statement

Balance Sheet

The company has $124.40 million in cash and $211.50 million in debt, giving a net cash position of -$87.10 million or -$0.92 per share.

Cash & Cash Equivalents	124.40M
Total Debt	211.50M
Net Cash	-87.10M
Net Cash Per Share	-$0.92
Equity (Book Value)	337.40M
Book Value Per Share	3.57
Working Capital	182.60M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $2.40 million and capital expenditures -$15.70 million, giving a free cash flow of -$13.30 million.

Operating Cash Flow	2.40M
Capital Expenditures	-15.70M
Depreciation & Amortization	51.80M
Net Borrowing	65.00M
Free Cash Flow	-13.30M
FCF Per Share	-$0.14

Full Cash Flow Statement

Margins

Gross margin is 69.96%, with operating and profit margins of -7.73% and -48.24%.

Gross Margin	69.96%
Operating Margin	-7.73%
Pretax Margin	-48.23%
Profit Margin	-48.24%
EBITDA Margin	-1.48%
EBIT Margin	-7.73%
FCF Margin	n/a

Dividends & Yields

Myriad Genetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.42%
Shareholder Yield	n/a
Earnings Yield	-72.01%
FCF Yield	-2.39%

Analyst Forecast

The average price target for Myriad Genetics is $6.25, which is 6.29% higher than the current price. The consensus rating is "Hold".

Price Target	$6.25
Price Target Difference	6.29%
Analyst Consensus	Hold
Analyst Count	9
Revenue Growth Forecast (3Y)	5.57%
EPS Growth Forecast (3Y)	65.44%

Stock Forecasts

Stock Splits

The last stock split was on March 26, 2009. It was a forward split with a ratio of 2:1.

Last Split Date	Mar 26, 2009
Split Type	Forward
Split Ratio	2:1

Scores

Myriad Genetics has an Altman Z-Score of -0.15 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.15
Piotroski F-Score	4